TECVAYLI® and TALVEY® REMS

The purpose of the TECVAYLI and TALVEY REMS is to mitigate the risks of Cytokine Release Syndrome (CRS) and neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), by:

• Ensuring prescribers are aware of the importance of monitoring for the signs and symptoms of CRS and neurologic toxicity, including ICANS, in patients exposed to TECVAYLI or TALVEY.

Access comprehensive information on Risk Evaluation and Mitigation Strategies for TECVAYLI and TALVEY at https://tec-talrems.com.